• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

卡那单抗在治疗选择有限的患者的难治性痛风性疾病中的应用：希腊沃拉阿斯克利皮翁综合医院风湿病诊所的经验。

The use of Canakinumab in treating resistant gouty disease in patients with limited therapeutic options: The experience of the Rheumatology Clinic of Asklipeion General Hospital of Voula, Greece.

作者信息

Theotikos Evangelos, Raftakis Ioannis, Elezoglou Antonia, Antoniadis Christodoulos

机构信息

Asklipeion General Hospital of Voula, Athens, Greece.

出版信息

Mediterr J Rheumatol. 2017 Mar 28;28(1):48-51. doi: 10.31138/mjr.28.1.48. eCollection 2017 Mar.

DOI:10.31138/mjr.28.1.48
PMID:32185254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7045930/
Abstract

Gout is an autoinflammatory disease caused by monosodium urate mono hydrate crystal deposition in tissues or the supersaturation of extracellular fluids of uric acid. In this study, we are going to report the experience of the Asklepeion Voula Rheumatology Clinic, treating four patients with gouty arthritis who received Canakinumab.

摘要

痛风是一种自身炎症性疾病，由单水尿酸钠晶体在组织中沉积或细胞外液尿酸过饱和所致。在本研究中，我们将报告阿斯克勒庇俄斯·武拉风湿病诊所治疗4例接受卡那单抗治疗的痛风性关节炎患者的经验。

相似文献

1
The use of Canakinumab in treating resistant gouty disease in patients with limited therapeutic options: The experience of the Rheumatology Clinic of Asklipeion General Hospital of Voula, Greece.卡那单抗在治疗选择有限的患者的难治性痛风性疾病中的应用：希腊沃拉阿斯克利皮翁综合医院风湿病诊所的经验。
Mediterr J Rheumatol. 2017 Mar 28;28(1):48-51. doi: 10.31138/mjr.28.1.48. eCollection 2017 Mar.
2
A Beacon in the Dark: Canakinumab. A New Therapeutic Perspective in Chronic Tophaceous Gout.黑暗中的灯塔：卡那单抗。慢性痛风石性痛风的新治疗视角。
Rheumatol Ther. 2018 Jun;5(1):303-310. doi: 10.1007/s40744-018-0104-8. Epub 2018 Mar 9.
3
Evidence for a promoter of urate crystal formation in gouty synovial fluid.痛风性滑液中尿酸盐晶体形成促进因子的证据。
Ann Rheum Dis. 1991 Aug;50(8):558-61. doi: 10.1136/ard.50.8.558.
4
The Way Forward: Practical Clinical Considerations for the Use of Canakinumab in Patients With Difficult-to-Treat Gouty Arthritis.前进之路：在难治性痛风性关节炎患者中使用卡那单抗的实际临床考量
Joint Bone Spine. 2015 Oct;82 Suppl 1:eS30-2. doi: 10.1016/S1297-319X(15)30005-1.
5
Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout).一水合尿酸钠晶体沉积病（痛风）的临床方面
Rheum Dis Clin North Am. 1988 Aug;14(2):377-94.
6
Extract Alleviates Monosodium Urate-Induced Acute Gouty Arthritis in Rats by Inhibiting Uric Acid and Inflammation.提取物通过抑制尿酸和炎症减轻大鼠尿酸钠诱导的急性痛风性关节炎。
Evid Based Complement Alternat Med. 2020 Apr 21;2020:3095624. doi: 10.1155/2020/3095624. eCollection 2020.
7
[Value of dual-energy computed tomography in the diagnosis of gouty arthritis].[双能计算机断层扫描在痛风性关节炎诊断中的价值]
Nan Fang Yi Ke Da Xue Xue Bao. 2015 Mar;35(3):384-6.
8
The popliteal groove region: A new target for the detection of monosodium urate crystal deposits in patients with gout. An ultrasound study.腘窝区域：痛风患者尿酸单钠晶体沉积检测的新靶点。一项超声研究。
Joint Bone Spine. 2019 Jan;86(1):89-94. doi: 10.1016/j.jbspin.2018.06.008. Epub 2018 Jul 17.
9
Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation.研究绿原酸的抗痛风活性：改善高尿酸血症和痛风炎症。
Am J Chin Med. 2014;42(6):1471-83. doi: 10.1142/S0192415X1450092X.
10
Clinical utility of dual-energy CT for gout diagnosis.双能CT在痛风诊断中的临床应用价值
Clin Imaging. 2015 Sep-Oct;39(5):880-5. doi: 10.1016/j.clinimag.2014.12.015. Epub 2015 Feb 11.

本文引用的文献

1
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.使用白细胞介素-1阻断疗法治疗风湿性疾病及合并症。
Rheumatology (Oxford). 2015 Dec;54(12):2134-44. doi: 10.1093/rheumatology/kev269. Epub 2015 Jul 23.
2
Interleukin-1 as a therapeutic target in gout.白细胞介素-1作为痛风的治疗靶点。
Curr Opin Rheumatol. 2015 Mar;27(2):156-63. doi: 10.1097/BOR.0000000000000143.
3
Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures.
根据多种痛风性关节炎相关健康结局指标比较卡那单抗与曲安奈德的疗效。
Int J Clin Pract. 2014 Dec;68(12):1503-7. doi: 10.1111/ijcp.12521. Epub 2014 Oct 9.
4
Prophylaxis for acute gout flares after initiation of urate-lowering therapy.降尿酸治疗开始后急性痛风发作的预防。
Rheumatology (Oxford). 2014 Nov;53(11):1920-6. doi: 10.1093/rheumatology/keu157. Epub 2014 Apr 23.
5
Treatment of acute gout.急性痛风的治疗
Rheum Dis Clin North Am. 2014 May;40(2):329-41. doi: 10.1016/j.rdc.2014.01.008. Epub 2014 Feb 19.
6
Innate immunity functional gene polymorphisms and gout susceptibility.固有免疫功能基因多态性与痛风易感性。
Gene. 2013 Jul 25;524(2):412-4. doi: 10.1016/j.gene.2013.04.039. Epub 2013 Apr 29.
7
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.卡那奴单抗治疗治疗选择有限的急性痛风性关节炎患者的疗效：两项随机、多中心、活性对照、双盲试验及其初步扩展的结果。
Ann Rheum Dis. 2012 Nov;71(11):1839-48. doi: 10.1136/annrheumdis-2011-200908. Epub 2012 May 14.
8
Prevalence of contraindications and prescription of pharmacologic therapies for gout.痛风的禁忌症和药物治疗处方的流行情况。
Am J Med. 2011 Feb;124(2):155-63. doi: 10.1016/j.amjmed.2010.09.012.
9
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.卡那单抗治疗难治性痛风性关节炎急性发作：一项多中心、II期、剂量范围研究的结果
Arthritis Rheum. 2010 Oct;62(10):3064-76. doi: 10.1002/art.27600.
10
Mechanisms of uric acid crystal-mediated autoinflammation.尿酸盐晶体介导的自身炎症机制。
Immunol Rev. 2010 Jan;233(1):218-32. doi: 10.1111/j.0105-2896.2009.00860.x.